按肉瘤样特征丰度对肾细胞癌患者分层可揭示生存差异及潜在病理生物学
本研究在单中心104例接受肾切除术的肉瘤样肾细胞癌(sRCC)患者中,按肉瘤样特征≥10%或<10%分为肉瘤样高组与低组。肉瘤样高组总生存显著短于低组(中位14.5 vs 62.9个月,p<0.001),在临床局限性疾病中无转移生存亦显著更短(中位10.7 vs 39.0个月,p=0.043)。转录组分析显示高组上调细胞周期/增殖、上皮-间质转化、活性氧及干扰素-α信号等九条通路。
要点
- 按肉瘤样特征≥10%与<10%分层,肉瘤样高组总生存显著短于低组(中位14.5 vs 62.9个月,p<0.001)。
- 临床局限性疾病中,肉瘤样高组无转移生存显著短于低组(中位10.7 vs 39.0个月,p=0.043)。
- 转录组分析示肉瘤样高组上调细胞周期/增殖、上皮-间质转化、活性氧及干扰素-α信号等九条通路。
核心结论
- sRCC按肉瘤样特征高与低分层具有预后价值,并揭示临床结局差异背后的关键生物学。
- 作者认为未来将sRCC分为肉瘤样高与低组可能有助于指导研究和患者管理。
研究设计与样本
- 单中心104例连续接受肾切除术的sRCC患者队列,按肿瘤内肉瘤样特征丰度分为肉瘤样高(≥10%,n=52)与肉瘤样低(<10%,n=52)。
- 对45例sRCC肿瘤行转录组分析,其中肉瘤样高组n=24、肉瘤样低组n=21。
主要发现
- 肉瘤样高组(n=52)总生存显著短于肉瘤样低组(n=52),中位14.5 vs 62.9个月(p<0.001),多变量分析证实。
- 临床局限性疾病患者中,肉瘤样高组无转移生存显著短于肉瘤样低组,中位10.7 vs 39.0个月(p=0.043)。
- 转录组分析显示肉瘤样高组(n=24)较肉瘤样低组(n=21)显著上调九条与细胞周期/增殖、上皮-间质转化、活性氧及干扰素-α信号相关的 hallmark 通路。
- 转录组聚类显示肉瘤样高肿瘤以增殖性、炎症性和免疫效应表型为主,肉瘤样低肿瘤以缺氧/血管生成表型为主。
临床怎么用
- 作者认为未来将sRCC分为肉瘤样高与低组可能有助于指导研究和患者管理。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Sarcomatoid renal cell carcinoma (sRCC) is histologically heterogeneous, with variable sarcomatoid amounts intermixed within epithelial carcinoma. However, the current classification for this aggressive disease is homogeneous and agnostic to the sarcomatoid proportion. We investigated whether sRCC subclassification has prognostic value and can reveal the biology underlying dedifferentiation and its clinical aggressiveness. On the basis of the intratumoral abundance of sarcomatoid features, cases were classified as sarcomatoid-high (≥10% sarcomatoid features) or sarcomatoid-low (<10% sarcomatoid features) in a cohort of 104 consecutive patients with sRCC undergoing nephrectomy at a single center. In comparison to sarcomatoid-low patients (n = 52), sarcomatoid-high patients (n = 52) had significantly shorter overall survival (median 14.5 vs 62.9 mo; p < 0.001), which was confirmed on multivariable analysis, and significantly shorter median metastasis-free survival among patients with clinically localized disease (10.7 vs 39.0 mo; p = 0.043). Transcriptomic analyses of 45 sRCC tumors revealed significant upregulation of nine hallmark pathways related to cell cycle/proliferation, epithelial-to-mesenchymal transition, reactive oxidative species, and interferon-α signaling among sarcomatoid-high (n = 24) versus sarcomatoid-low (n = 21) tumors. Categorization into transcriptomic clusters revealed predominance of proliferative, inflammatory, and immune effector phenotypes among sarcomatoid-high tumors, versus a hypoxia/angiogenesis phenotype among sarcomatoid-low tumors. Overall, these findings indicate prognostic value for sRCC subclassification into high versus low sarcomatoid groups and highlight key biology underlying the differences in clinical outcomes. PATIENT SUMMARY: Sarcomatoid renal cell carcinoma (sRCC) is a highly aggressive form of kidney cancer. The percentage of sarcomatoid features varies among tumors, but sRCC is still defined as a single kidney cancer type. Our results show that grouping patients according to their percentage of sarcomatoid features improves prediction of whether their tumors will become metastatic or lethal, and reveal molecular differences that may be important for this disease. Future assignment of sRCC to high and low sarcomatoid groups may help in guiding research and patient management.
引用
- Salgia NJ, Aubrecht WM, Wang L, et al. Stratification of Patients with Renal Cell Carcinoma by the Abundance of Sarcomatoid Features Reveals Differences in Survival and the Underlying Pathobiology. Eur Urol Oncol. 2024. PMID: 38480032. doi:10.1016/j.euo.2024.02.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。